Quarterly ResultJul 29, 2026, 07:26 AM
Anika Q2 Revenue $32.6M, Adj. EBITDA $7.1M; Raises FY26 Guidance
AI Summary
Anika Therapeutics reported strong second-quarter 2026 financial results, with total revenue increasing 16% to $32.6 million and adjusted EBITDA reaching $7.1 million, the highest since 2020. The company raised its full-year 2026 revenue growth guidance to 5-10% and adjusted EBITDA margin to 13-17% due to strong first-half performance and operational improvements. However, 2027 Commercial Channel revenue guidance was revised downwards to 5-15% due to a new policy excluding unapproved products like Hyalofast, reflecting regulatory timing uncertainty.
Key Highlights
- Q2 2026 total revenue increased 16% year-over-year to $32.6 million.
- Commercial Channel revenue grew 17% to a record $13.9 million.
- Adjusted EBITDA for Q2 was $7.1 million, with a 22% margin, highest since 2020.
- Net income for Q2 was $3.3 million, or $0.24 per diluted share.
- Full-year 2026 revenue growth guidance raised to 5-10% from 1-9%.
- Full-year 2026 Adjusted EBITDA margin guidance raised to 13-17% from 5-10%.
- 2027 Commercial Channel revenue growth guidance revised to 5-15% due to Hyalofast exclusion.
- Cingal NDA development and Hyalofast PMA discussions with FDA are ongoing.
Price Impact
More from ANIK